Show simple item record

dc.contributor.authorAk, Naziye
dc.contributor.authorSaip, Pinar
dc.contributor.authorMinareci, Yagmur
dc.date.accessioned2021-12-10T10:46:42Z
dc.date.available2021-12-10T10:46:42Z
dc.date.issued2021
dc.identifier.citationAk N., Minareci Y., Saip P., "Skeletal system as a rare metastatic site in patients with ovarian carcinoma", INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, cilt.31, sa.8, ss.1125-1131, 2021
dc.identifier.issn1048-891X
dc.identifier.othervv_1032021
dc.identifier.otherav_53c4d145-43e0-43f0-9ded-585aeccc031d
dc.identifier.urihttp://hdl.handle.net/20.500.12627/170557
dc.identifier.urihttps://doi.org/10.1136/ijgc-2021-002486
dc.description.abstractObjective To evaluate the frequency and predictors of bone metastasis in patients with ovarian cancer and to determine prognostic factors associated with this finding. Methods Patients diagnosed with ovarian cancer between January 2009 and December 2019 were evaluated. Patients with radiologically or pathologically confirmed bone metastasis were included in the study. Survival was analyzed using Kaplan-Meier curves and compared using the log-rank test. Multivariate analysis of prognostic factors related to survival was performed using the Cox proportional hazards model. Results Nineteen (2.6%) of 736 patients had bone metastases. Patients with clear cell histology had a higher risk of bone metastases than patients with the other epithelial histology groups (12.3% vs 2.1%, p<0.001). Overall survival was significantly lower in patients diagnosed with bone metastasis at the time of cancer diagnosis than in those diagnosed with bone metastasis during the course of the disease (median 63 vs 6.1 months, p<0.001). However, when the survival time after the development of bone metastasis was examined, no difference was found between patients with metastasis at the time of diagnosis and at the time of first or later progression (median 13.6 vs 4 months, p=0.09). In addition, the median survival of patients with clear cell histology after bone metastasis did not differ statistically from that of patients with other epithelial histology (median 22 vs 7.5 months; p=0.13). In the clear cell subgroup, bone metastasis was an independent prognostic factor for survival after multivariate analysis. For all patients, the stage at diagnosis and serum CA125 and alkaline phosphatase levels at the time of bone metastasis were prognostic factors for survival. Discussion Bone metastasis is rare in patients with ovarian cancer. However, the risk of bone metastasis is highest in patients with clear cell histology.
dc.language.isoeng
dc.subjectOnkoloji
dc.subjectCerrahi Tıp Bilimleri
dc.subjectKadın Hastalıkları ve Doğum
dc.subjectObstetrics and Gynecology
dc.subjectOncology
dc.subjectHealth Sciences
dc.subjectDahili Tıp Bilimleri
dc.subjectİç Hastalıkları
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKADIN HASTALIKLARI & DOĞUM
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleSkeletal system as a rare metastatic site in patients with ovarian carcinoma
dc.typeMakale
dc.relation.journalINTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
dc.contributor.departmentİstanbul Üniversitesi , ,
dc.identifier.volume31
dc.identifier.issue8
dc.identifier.startpage1125
dc.identifier.endpage1131
dc.contributor.firstauthorID2703376


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record